Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biocryst, Coherus, Hansoh, Novo Nordisk, Regeneron, Sumitomo.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Avadel, Biolinerx, Enterome, Faron, GC Biopharma, Genentech, Merck, Pfizer, Regeneron, Roche, Sanofi, Summit.
New and positive phase III cancer data for two monoclonal antibodies from two pharma giants opened the second day of the American Society of Clinical Oncology (ASCO) conference this past weekend.
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
At the 61st American Society of Clinical Oncology (ASCO) Annual Meeting, multiple companies presented clinical trial data showing their drugs and devices helped patients with pancreatic cancer live longer or improve their ability to respond to treatment.
Sanofi SA is to acquire Blueprint Medicines Inc. in a $9.5 billion deal that will give the French pharma ownership of a marketed rare disease immunotherapy heading toward blockbuster status, a follow-on product in phase II/III, and a phase II clinical program relevant to a number of autoimmune diseases.
RSS
